Trials / Unknown
UnknownNCT03058809
Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood
Evaluation of the Saftey and Efficacy of the Viatar™ Oncopheresis System in Removing Circulating Tumor Cells From Whole Blood
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Viatar LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will access the safety and efficacy of the Viatar™ Oncopheresis System to remove a meaningful quantity of circulating tumor cells from the blood of subjects' with breast, colon or prostate solid tumor cancers in a single treatment. CTC reduction will be measured as the change in circulating tumor cells as determined before and after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Oncopheresis | Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components. |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2019-04-01
- Completion
- 2019-05-01
- First posted
- 2017-02-23
- Last updated
- 2018-05-31
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03058809. Inclusion in this directory is not an endorsement.